PF-08046876
Phase 1RecruitingDevelopment Stage
Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Aug 20, 2025 → Jul 8, 2029
About PF-08046876
PF-08046876 is a phase 1 stage product being developed by Pfizer for Advanced/Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07090499. Target conditions include Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07090499 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors